ArticleHealth science reports2025
Did COVID-19 Pandemic Change the Course of Multiple Sclerosis? A Retrospective Eight-Year Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Did COVID-19 Pandemic Change the Course of Multiple Sclerosis? A Retrospective Eight-Year Study.Health science reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The COVID-19 pandemic was a special situation for patients treated with disease-modifying therapies (DMTs). Infections may provoke disease activity and determine the choice of DMTs. Moreover, DMTs create a potentially increased risk of infections. The study aimed to assess the impact of the COVID-19 pandemic and the importance of COVID-19 vaccination on the course of multiple sclerosis (MS). Methods: The 8-year single-center retrospective cohort study compared treatment changes and infection incidence in 115 MS patients before and during the COVID-19 pandemic, as well as COVID-19 incidence and severity before and after COVID-19 vaccination. A multivariate approach assessed the effects of specific factors (age, sex, disease duration, prognostic profile, disease activity before the pandemic, DMTs, and infections) on the course of MS. Results: Relapse activity was the most common reason for therapy change, with no significant differences (56.52% vs. 61.52%, Conclusions: The COVID-19 pandemic did not affect the course of MS in long-term follow-up. The only factor associated with relapse activity during the pandemic period was disease activity in the pre-pandemic period. COVID-19 vaccination may be an essential tool in the care of MS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.